nach oben

Erschienen in:

01.04.2021 | Original Article

Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice

verfasst von: Pranglada Jearjaroen, Kanet Pakdeepak, Chainarong Tocharus, Waraluck Chaichompoo, Apichart Suksamrarn, Jiraporn Tocharus

Erschienen in: Neurotoxicity Research | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

A high dose of dexamethasone induces neurodegeneration by initiating the inflammatory processes that lead to neural apoptosis. A dexamethasone administration model induces overproduction of amyloid-β (Aβ) and tau protein hyperphosphorylation and shows abnormalities of cholinergic function similar to Alzheimer’s disease (AD). This study aimed to investigate the protective effect of hexahydrocurcumin on the brain of dexamethasone-induced mice. The results showed that hexahydrocurcumin and donepezil attenuated the levels of amyloid precursor protein and β-secretase mRNA by reverse transcription polymerase chain reaction, decreased the expression of hyperphosphorylated tau, and improved synaptic function. Moreover, we found that hexahydrocurcumin treatment could decrease interleukin-6 levels by attenuating p65 of nuclear factor kappa-light-chain-enhancer (NF-κB) of activated beta cells. In addition, hexahydrocurcumin also decreased oxidative stress, as demonstrated by the expression of 4-hydroxynonenal and thereby prevented apoptosis. Therefore, our finding suggests that hexahydrocurcumin prevents dexamethasone-induced AD-like pathology and improves memory impairment.

Nur mit Berechtigung zugänglich

Abbasi M, Ilyas M, Sonia A, Shahwar D, Raza M, Khan K, Ashraf M, Afzal I, Ambreen N (2012) Curcumin and its derivatives: moderate inhibitors of acetylcholinesterase, butyrylcholinesterase and trypsin. SCI IRAN 19(6):1580–1583. https://doi.org/10.1016/j.scient.2012.10.014CrossRef

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. https://doi.org/10.1021/mp700113rCrossRefPubMed

Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR (2007) Differential regulation of BACE1 promoter activity by nuclear factor-κB in neurons and glia upon exposure to β-amyloid peptides. J Neurosci Res 85(6):1194–1204. https://doi.org/10.1002/jnr.21252CrossRefPubMed

Briggs R, Kennelly SP, O’Neill D (2016) Drug treatments in Alzheimer’s disease. Clin Med (Lond) 16(3):247–253. https://doi.org/10.7861/clinmedicine.16-3-247CrossRef

Buggia-Prevot V, Sevalle J, Rossner S, Checler F (2008) NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 283(15):10037–10047. https://doi.org/10.1074/jbc.M706579200CrossRefPubMed

Bustanji Y, Taha MO, Almasri IM, Al-Ghussein MA, Mohammad MK, Alkhatib HS (2009) Inhibition of glycogen synthase kinase by curcumin: investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 24(3):771–778. https://doi.org/10.1080/14756360802364377CrossRefPubMed

Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A (2010) Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 45:941–956. https://doi.org/10.1016/j.ejmech.2009.11.035CrossRefPubMed

Chen C-H, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y, Song W (2012) Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol 15(1):77–90. https://doi.org/10.1017/S1461145711000149CrossRefPubMed

Danilczuk Z, Sekita-Krzak J, Lupina T, Danilczuk M, Czerny K (2006) Influence of dizocilpine (MK-801) on neurotoxic effect of dexamethasone: behavioral and histological studies. Acta Neurobiol Exp (Wars) 66(3):215–226

Das TK, Jana P, Chakrabarti SK, Hamid A, Mas R (2019) Curcumin downregulates GSK3 and Cdk5 in scopolamine-induced Alzheimer’s disease rats abrogating Aβ 40/42 and tau hyperphosphorylation. J Alzheimers Dis Rep 3(1):257–267. https://doi.org/10.3233/ADR-190135CrossRefPubMedPubMedCentral

Ellman GL, Gourtney KD, Andres V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acethylcholinesterase activity. Biochem Phrmacol 7(2):88–95. https://doi.org/10.1016/0006-2952(61)90145-9CrossRef

Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006) Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci 26(35):9047–9056. https://doi.org/10.1523/JNEUROSCI.2797-06.2006CrossRefPubMedPubMedCentral

Hu S, Maiti P, Ma Q, Zuo X, Jones MR, Cole GM et al (2015) Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 15(6):629–637. https://doi.org/10.1586/14737175.2015.1044981CrossRefPubMedPubMedCentral

Hu W, Zhang Y, Wu W, Yin Y, Huang D, Wang Y et al (2016) Chronic glucocorticoids exposure enhances neurodegeneration in the frontal cortex and hippocampus via NLRP-1 inflammasome activation in male mice. Brain Behav Immun 52:58–70. https://doi.org/10.1016/j.bbi.2015.09.019CrossRefPubMed

Huang Y, Cao S, Zhang Q, Zhang H, Fan Y, Qiu F et al (2018) Biological and pharmacological effects of hexahydrocurcumin, a metabolite of curcumin. Arch Biochem Biophys 646:31–37. https://doi.org/10.1016/j.abb.2018.03.030CrossRefPubMed

Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry. 32(18):4693–4697. https://doi.org/10.1021/bi00069a001CrossRefPubMed

Joshi YB, Chu J, Praticò D (2012) Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer’s disease. J Alzheimers Dis 31(1):167–176. https://doi.org/10.3233/JAD-2012-120328CrossRefPubMed

Kang G, Kong P-J, Yuh Y-J, Lim S-Y, Yim S-V, Chun W, Kim S-S (2004) Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor κB bindings in BV2 microglial cells. J Pharmacol Sci 94(3):325–328. https://doi.org/10.1254/jphs.94.325CrossRefPubMed

Kar S, Slowikowski SP, Westaway D, Mount HT (2004) Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29(6):427–441PubMedPubMedCentral

Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004CrossRefPubMed

Ladner CJ, Lee JM (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57(8):719–731. https://doi.org/10.1097/00005072-199808000-00001CrossRefPubMed

LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci 8(7):499. https://doi.org/10.1038/nrn2168CrossRefPubMed

Lahiri DK (2004) Functional characterization of amyloid β precursor protein regulatory elements: rationale for the identification of genetic polymorphism. Ann N Y Acad Sci 1030(1):282–288. https://doi.org/10.1196/annals.1329.035CrossRefPubMed

Lee S-L, Huang W-J, Lin WW, Lee S-S, Chen C-H (2005) Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg Med Chem 13(22):6175–6181. https://doi.org/10.1016/j.bmc.2005.06.058CrossRefPubMed

Li W, Suwanwela NC, Patumraj S (2016) Curcumin by down-regulating NF-kB and elevating Nrf2, reduces brain edema and neurological dysfunction after cerebral I/R. Microvasc Res 106:117–127. https://doi.org/10.1016/j.mvr.2015.12.008CrossRefPubMed

Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE et al (2000) Neuronal–glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 20(1):149–155. https://doi.org/10.1523/JNEUROSCI.20-01-00149.2000CrossRefPubMedPubMedCentral

McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Montalto G (2017) Regulation of GSK-3 activity by curcumin, berberine and resveratrol: potential effects on multiple diseases. Adv Biol Regul 65:77–88. https://doi.org/10.1016/j.jbior.2017.05.005CrossRefPubMed

McEwen BS, Magarinos AM (2001) Stress and hippocampal plasticity: implications for the pathophysiology of affective disorders. Hum Psychopharmacol 16(S1):S7–S19. https://doi.org/10.1002/hup.266CrossRefPubMed

Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125. https://doi.org/10.1007/978-0-387-46401-5_3CrossRefPubMed

Morales NP, Sirijaroonwong S, Yamanont P, Phisalaphong C (2015) electron paramagnetic resonance study of the free radical scavenging capacity of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 38(10):1478–1483. https://doi.org/10.1248/bpb.b15-00209CrossRefPubMed

Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH (2020) BACE1 inhibitors: current status and future directions in treating Alzheimer’s disease. Med Res Rev 40(1):339–384. https://doi.org/10.1002/med.21622CrossRefPubMed

Ohta Y, Darwish M, Hishikawa N, Yamashita T, Sato K, Takemoto M et al (2017) Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Geriatr Gerontol Int 17(11):1843–1848. https://doi.org/10.1111/ggi.12971CrossRefPubMed

Naqvi F, Saleem S, Naqvi F, Batool Z, Sadir S, Tabassum S, Ahmed S, Liaquat L, Haider S (2019) Curcumin lessens unpredictable chronic mild stress-induced depression and memory deficits by modulating oxidative stress and cholinergic activity. Pak J Pharm Sci 32(4(Supplementary)):1893–1900PubMed

Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J (2018) Amyloid-β and tau complexity-towards improved biomarkers and targeted therapies. Nat Rev Neurol 14(1):22–39. https://doi.org/10.1038/nrneurol.2017.162CrossRefPubMed

Ruksee N, Tongjaroenbuangam W, Mahanam T, Govitrapong P (2014) Melatonin pretreatment prevented the effect of dexamethasone negative alterations on behavior and hippocampal neurogenesis in the mouse brain. J Steroid Biochem Mol Biol 143:72–80. https://doi.org/10.1016/j.jsbmb.2014.02.011CrossRefPubMed

Sambamurti K, Kinsey R, Maloney B, Ge Y-W, Lahiri DK (2004) Gene structure and organization of the human β-secretase (BACE) promoter. FASEB J 18(9):1034–1036. https://doi.org/10.1096/fj.03-1378fjeCrossRefPubMed

Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP (2007) Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 30(1):74–78. https://doi.org/10.1248/bpb.30.74CrossRefPubMed

Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ (2012) Epidemiology of dementias and Alzheimer’s disease. Arch Med Res 43(8):600–608. https://doi.org/10.1016/j.arcmed.2012.11.003CrossRefPubMed

Srimuangwong K, Tocharus C, Chintana PY, Suksamrarn A, Tocharus J (2012) Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 18(19):2383. https://doi.org/10.3748/wjg.v18.i19.2383CrossRefPubMedPubMedCentral

Tang M, Taghibiglou C (2017) The mechanisms of action of curcumin in Alzheimer’s disease. J Alzheimers Dis 58(4):1003–1016. https://doi.org/10.3233/JAD-170188CrossRefPubMed

Tongjaroenbuangam W, Ruksee N, Mahanam T, Govitrapong P (2013) Melatonin attenuates dexamethasone-induced spatial memory impairment and dexamethasone-induced reduction of synaptic protein expressions in the mouse brain. Neurochem Int 63(5):482–491. https://doi.org/10.1016/j.neuint.2013.08.011CrossRefPubMed

Tyagi E, Agrawal R, Nath C, Shukla R (2010) Effect of melatonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain. Eur J Pharmacol 640(1–3):206–210. https://doi.org/10.1016/j.ejphar.2010.04.041CrossRefPubMed

Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P et al (1999) β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735–741. https://doi.org/10.1126/science.286.5440.735CrossRefPubMed

Wang H, Sui H, Zheng Y, Jiang Y, Shi Y, Liang J, Zhao L (2019) Curcumin-primed exosomes potently ameliorate cognitive function in AD mice by inhibiting hyperphosphorylation of the Tau protein through the AKT/GSK-3β pathway. Nanoscale. 11(15):7481–7496. https://doi.org/10.1039/c9nr01255aCrossRefPubMed

Wicha P, Tocharus J, Janyou A, Jittiwat J, Changtam C, Suksamrarn A et al (2017) Hexahydrocurcumin protects against cerebral ischemia/reperfusion injury, attenuates inflammation, and improves antioxidant defenses in a rat stroke model. PLoS One 12(12):e0189211. https://doi.org/10.1371/journal.pone.0189211CrossRefPubMedPubMedCentral

Wildburger NC, Laezza F (2012) Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase. Front Mol Neurosci 5(80). https://doi.org/10.3389/fnmol.2012.00080

Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM, Winblad B et al (2017) The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement 13(1):1–7. https://doi.org/10.1016/j.jalz.2016.07.150CrossRefPubMedPubMedCentral

Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7):5892–5901. https://doi.org/10.1074/jbc.M404751200CrossRefPubMed

Zheng K, Dai X, Wu X, Wei Z, Fang W, Zhu Y, Zhang J, Chen X (2017) Curcumin ameliorates memory decline via inhibiting BACE1 expression and β-amyloid pathology in 5× FAD transgenic mice. Mol Neurobiol 54(3):1967–1977. https://doi.org/10.1007/s12035-016-9802-9CrossRefPubMed

Zheng W-H, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 115(1):201–211. https://doi.org/10.1016/s0306-4522(02)00404-9CrossRefPubMed

Titel: Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice
verfasst von: Pranglada Jearjaroen
Kanet Pakdeepak
Chainarong Tocharus
Waraluck Chaichompoo
Apichart Suksamrarn
Jiraporn Tocharus
Publikationsdatum: 01.04.2021
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 2/2021
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-020-00269-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes

Involvement of Mitophagy in Aluminum Oxide Nanoparticle–Induced Impairment of Learning and Memory in Mice

A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors

Anacardic Acid Complexes as Possible Agents Against Alzheimer’s Disease Through Their Antioxidant, In vitro, and In silico Anticholinesterase and Ansiolic Actions

Alpha-Synuclein Aggregates Associated with Mitochondria in Tunnelling Nanotubes